Brief: Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases
25/03/2025 12:38
March 25 (Reuters) - Bausch + Lomb Corp BLCO.TO: CHARACTER BIOSCIENCES RAISES $93 MILLION SERIES B TO ADVANCE PRECISION MEDICINE FOR PROGRESSIVE EYE DISEASES CHARACTER BIOSCIENCES : FUNDING WAS CO-LED BY INVESTORS AMOON & LUMA GROUP, WITH ADDITIONAL PARTICIPATION FROM BAUSCH + LOMB Source text: ID:nBw95njd9a Further company coverage: BLCO.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser